A share price of Beam Therapeutics Inc [BEAM] is currently trading at $27.42, up 3.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 5.02% over the last week, with a monthly amount glided 3.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on March 10, 2025, when Scotiabank upgraded its rating to a Sector Outperform but kept the price target unchanged to $40 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on January 29, 2025. On November 06, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $39 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. H.C. Wainwright initiated its recommendation with a Buy and recommended $80 as its price target on July 23, 2024. JP Morgan upgraded its rating to Overweight for this stock on January 29, 2024, and upped its price target to $40. In a note dated December 15, 2023, BofA Securities downgraded an Neutral rating on this stock but restated the target price of $35.
Beam Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $20.84 and $37.49. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $27.42 at the most recent close of the market. An investor can expect a potential return of 44.06% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
Trailing Twelve Months sales for Beam Therapeutics Inc [NASDAQ:BEAM] were 63.52M which represents -90.49% decline. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -6.54%, Pretax Profit Margin comes in at -5.93%, and Net Profit Margin reading is -5.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.46 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.63 points at the first support level, and at 25.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.35, and for the 2nd resistance point, it is at 29.28.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Beam Therapeutics Inc [NASDAQ:BEAM] is 4.82. In addition, the Quick Ratio stands at 4.82 and the Cash Ratio stands at 1.55. Considering the valuation of this stock, the price to sales ratio is 41.52, the price to book ratio is 3.13.
Transactions by insiders
Recent insider trading involved Cavanagh Bethany J, SVP, Finance and Treasurer, that happened on Feb 18 ’25 when 6287.0 shares were sold. Chief Legal Officer, Bellon Christine completed a deal on Feb 14 ’25 to sell 10000.0 shares. Meanwhile, Officer CHRISTINE BELLON bought 10000.0 shares on Feb 14 ’25.
